TY - JOUR AU - Barclay, A. N. AU - Clark, M. J. AU - McCaughan, G. W. PY - 1986 DA - 1986// TI - Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure JO - Bioch Soc Symp VL - 51 ID - Barclay1986 ER - TY - JOUR AU - Clark, M. J. AU - Gagnon, J. AU - Williams, A. F. AU - Barclay, A. N. PY - 1985 DA - 1985// TI - MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain JO - EMBO J VL - 4 UR - https://doi.org/10.1002/j.1460-2075.1985.tb02324.x DO - 10.1002/j.1460-2075.1985.tb02324.x ID - Clark1985 ER - TY - JOUR AU - Wright, G. J. AU - Puklavec, M. J. AU - Willis, A. C. PY - 2000 DA - 2000// TI - Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function JO - Immunity. VL - 13 UR - https://doi.org/10.1016/S1074-7613(00)00023-6 DO - 10.1016/S1074-7613(00)00023-6 ID - Wright2000 ER - TY - JOUR AU - Wright, G. J. AU - Jones, M. AU - Puklavec, M. J. AU - Brown, M. H. AU - Barclay, A. N. PY - 2001 DA - 2001// TI - The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans JO - Immunology. VL - 102 UR - https://doi.org/10.1046/j.1365-2567.2001.01163.x DO - 10.1046/j.1365-2567.2001.01163.x ID - Wright2001 ER - TY - JOUR AU - Clark, D. A. AU - Keil, A. AU - Chen, Z. AU - Markert, U. AU - Manuel, J. AU - Gorczynski, R. M. PY - 2003 DA - 2003// TI - Placental trophoblast from successful human pregnancies expresses the tolerance signaling molecule, CD200 (OX-2) JO - Am J Reprod Immunol VL - 50 UR - https://doi.org/10.1034/j.1600-0897.2003.00086.x DO - 10.1034/j.1600-0897.2003.00086.x ID - Clark2003 ER - TY - JOUR AU - Webb, M. AU - Barclay, A. N. PY - 1984 DA - 1984// TI - Localisation of the MRC OX-2 glycoprotein on the surfaces of neurons JO - J Neurochem VL - 43 UR - https://doi.org/10.1111/j.1471-4159.1984.tb12844.x DO - 10.1111/j.1471-4159.1984.tb12844.x ID - Webb1984 ER - TY - JOUR AU - Barclay, A. N. AU - Wright, G. J. AU - Brooke, G. AU - Brown, M. H. PY - 2002 DA - 2002// TI - CD200 and membrane protein interactions in the control of myeloid cells JO - Trends Immunol VL - 23 UR - https://doi.org/10.1016/S1471-4906(02)02223-8 DO - 10.1016/S1471-4906(02)02223-8 ID - Barclay2002 ER - TY - JOUR AU - Wright, G. J. AU - Cherwinski, H. AU - Foster-Cuevas, M. PY - 2003 DA - 2003// TI - Characterization of the CD200 receptor family in mice and humans and their interactions with CD200 JO - J Immunol VL - 171 UR - https://doi.org/10.4049/jimmunol.171.6.3034 DO - 10.4049/jimmunol.171.6.3034 ID - Wright2003 ER - TY - JOUR AU - Coles, S. J. AU - Wang, E. C. Y. AU - Man, S. PY - 2011 DA - 2011// TI - CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia JO - Leukemia. VL - 25 UR - https://doi.org/10.1038/leu.2011.1 DO - 10.1038/leu.2011.1 ID - Coles2011 ER - TY - STD TI - Gorczynski R. CD200:CD200R-mediated regulation of immunity. ISRN Immunol. 2012;2012. ID - ref10 ER - TY - JOUR AU - Holmannova, D. AU - Kolackova, M. AU - Kondelkova, K. AU - Kunes, P. AU - Krejsek, J. AU - Andrys, C. PY - 2012 DA - 2012// TI - CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; part I: CD200/CD200R structure, activation, and function JO - Acta Med (Hradec Kralove) VL - 55 UR - https://doi.org/10.14712/18059694.2015.68 DO - 10.14712/18059694.2015.68 ID - Holmannova2012 ER - TY - JOUR AU - Prendergast, G. C. AU - Smith, C. AU - Thomas, S. PY - 2014 DA - 2014// TI - Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer JO - Cancer Immunol Immunother VL - 63 UR - https://doi.org/10.1007/s00262-014-1549-4 DO - 10.1007/s00262-014-1549-4 ID - Prendergast2014 ER - TY - JOUR AU - Rygiel, T. P. AU - Meyaard, L. PY - 2012 DA - 2012// TI - CD200R signaling in tumor tolerance and inflammation: a tricky balance JO - Curr Opin Immunol VL - 24 UR - https://doi.org/10.1016/j.coi.2012.01.002 DO - 10.1016/j.coi.2012.01.002 ID - Rygiel2012 ER - TY - JOUR AU - McWhirter, J. R. AU - Kretz-Rommel, A. AU - Saven, A. PY - 2006 DA - 2006// TI - Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation JO - Proc Natl Acad Sci U S A VL - 103 UR - https://doi.org/10.1073/pnas.0510081103 DO - 10.1073/pnas.0510081103 ID - McWhirter2006 ER - TY - JOUR AU - Moreaux, J. AU - Hose, D. AU - Reme, T. AU - Jourdan, E. AU - Hundemer, M. AU - Legouffe, E. PY - 2006 DA - 2006// TI - CD200 is a new prognostic factor in multiple myeloma JO - Blood. VL - 108 UR - https://doi.org/10.1182/blood-2006-06-029355 DO - 10.1182/blood-2006-06-029355 ID - Moreaux2006 ER - TY - JOUR AU - Siva, A. AU - Xin, H. AU - Qin, F. AU - Oltean, D. AU - Bowdish, K. S. AU - Kretz-Rommel, A. PY - 2008 DA - 2008// TI - Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200 JO - Cancer Immunol Immunother VL - 57 UR - https://doi.org/10.1007/s00262-007-0429-6 DO - 10.1007/s00262-007-0429-6 ID - Siva2008 ER - TY - JOUR AU - Kawasaki, B. T. AU - Mistree, T. AU - Hurt, E. M. AU - Kalathur, M. AU - Farrar, W. L. PY - 2007 DA - 2007// TI - Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells JO - Biochem Biophys Res Commun VL - 364 UR - https://doi.org/10.1016/j.bbrc.2007.10.067 DO - 10.1016/j.bbrc.2007.10.067 ID - Kawasaki2007 ER - TY - JOUR AU - Alapat, D. AU - Coviello-Malle, J. M. AU - Owens, R. PY - 2012 DA - 2012// TI - Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma JO - Am J Clin Pathol VL - 137 UR - https://doi.org/10.1309/AJCP59UORCYZEVQO DO - 10.1309/AJCP59UORCYZEVQO ID - Alapat2012 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Norde, W. J. AU - Hobo, W. AU - Voort, R. AU - Dolstra, H. PY - 2012 DA - 2012// TI - Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2012-02-412510 DO - 10.1182/blood-2012-02-412510 ID - Norde2012 ER - TY - JOUR AU - Ramsay, A. G. PY - 2013 DA - 2013// TI - Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity JO - Br J Haematol VL - 162 UR - https://doi.org/10.1111/bjh.12380 DO - 10.1111/bjh.12380 ID - Ramsay2013 ER - TY - JOUR AU - Pallasch, C. P. AU - Ulbrich, S. AU - Brinker, R. AU - Hallek, M. AU - Uger, R. A. AU - Wendtner, C. M. PY - 2009 DA - 2009// TI - Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade JO - Leuk Res VL - 33 UR - https://doi.org/10.1016/j.leukres.2008.08.021 DO - 10.1016/j.leukres.2008.08.021 ID - Pallasch2009 ER - TY - JOUR AU - Kretz-Rommel, A. AU - Qin, F. AU - Dakappagari, N. PY - 2007 DA - 2007// TI - CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy JO - J Immunol VL - 178 UR - https://doi.org/10.4049/jimmunol.178.9.5595 DO - 10.4049/jimmunol.178.9.5595 ID - Kretz-Rommel2007 ER - TY - JOUR AU - Gorczynski, R. M. AU - Chen, Z. AU - Diao, J. AU - Khatri, I. AU - Wong, K. AU - Yu, K. AU - Behnke, J. PY - 2010 DA - 2010// TI - Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice JO - Breast Cancer Res Treat VL - 123 UR - https://doi.org/10.1007/s10549-009-0667-8 DO - 10.1007/s10549-009-0667-8 ID - Gorczynski2010 ER - TY - JOUR AU - Osmana, A. A. AU - Eissaa, D. G. AU - Moussab, M. M. PY - 2014 DA - 2014// TI - CD200 is an independent prognostic factor in multiple myeloma JO - Egyptian J Haematol VL - 39 UR - https://doi.org/10.4103/1110-1067.148254 DO - 10.4103/1110-1067.148254 ID - Osmana2014 ER - TY - JOUR AU - Kretz-Rommel, A. AU - Qin, F. AU - Dakappagari, N. AU - Cofiell, R. AU - Faas, S. J. AU - Bowdish, K. S. PY - 2008 DA - 2008// TI - Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy JO - J Immunol VL - 180 UR - https://doi.org/10.4049/jimmunol.180.2.699 DO - 10.4049/jimmunol.180.2.699 ID - Kretz-Rommel2008 ER - TY - JOUR AU - Ascierto, P. A. AU - Marincola, F. M. PY - 2015 DA - 2015// TI - 2015: the year of anti-PD-1/PD-L1s against melanoma and beyond JO - EBioMedicine. VL - 2 UR - https://doi.org/10.1016/j.ebiom.2015.01.011 DO - 10.1016/j.ebiom.2015.01.011 ID - Ascierto2015 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Ribas, A. AU - Puzanov, I. AU - Dummer, R. PY - 2015 DA - 2015// TI - Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00083-2 DO - 10.1016/S1470-2045(15)00083-2 ID - Ribas2015 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Wolchok, J. D. PY - 2014 DA - 2014// TI - Anti-programmed death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial JO - Lancet. VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60958-2 DO - 10.1016/S0140-6736(14)60958-2 ID - Robert2014 ER - TY - JOUR AU - Topalian, S. L. AU - Sznol, M. AU - McDermott, D. F. PY - 2014 DA - 2014// TI - Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0105 DO - 10.1200/JCO.2013.53.0105 ID - Topalian2014 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. PY - 2015 DA - 2015// TI - Combined nivolumab and ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Wolchok, J. D. AU - Kluger, H. AU - Callahan, M. K. PY - 2013 DA - 2013// TI - Nivolumab plus ipilimumab in advanced melanoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1302369 DO - 10.1056/NEJMoa1302369 ID - Wolchok2013 ER - TY - JOUR AU - Allison, J. P. PY - 2015 DA - 2015// TI - Immune checkpoint blockade in cancer therapy. The 2015 Lasker DeBakey clinical medical research award JO - JAMA. VL - 314 UR - https://doi.org/10.1001/jama.2015.11929 DO - 10.1001/jama.2015.11929 ID - Allison2015 ER - TY - JOUR AU - Jacob, J. A. PY - 2015 DA - 2015// TI - Cancer immunotherapy researchers focus on refining checkpoint blockade therapies JO - JAMA. VL - 314 UR - https://doi.org/10.1001/jama.2015.10795 DO - 10.1001/jama.2015.10795 ID - Jacob2015 ER - TY - JOUR AU - Jing, W. AU - Gershan, J. A. AU - Weber, J. PY - 2015 DA - 2015// TI - Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-014-0043-z DO - 10.1186/s40425-014-0043-z ID - Jing2015 ER - TY - JOUR AU - Hallek, M. AU - Cheson, B. D. AU - Catovsky, D. AU - Caligaris-Cappio, F. AU - Dighiero, G. PY - 2008 DA - 2008// TI - Do¨hner H, et al. guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines JO - Blood. VL - 111 UR - https://doi.org/10.1182/blood-2007-06-093906 DO - 10.1182/blood-2007-06-093906 ID - Hallek2008 ER - TY - JOUR AU - Durie, B. G. AU - Harousseau, J. L. AU - Miguel, J. S. PY - 2006 DA - 2006// TI - International uniform response criteria for multiple myeloma JO - Leukemia. VL - 20 UR - https://doi.org/10.1038/sj.leu.2404284 DO - 10.1038/sj.leu.2404284 ID - Durie2006 ER - TY - JOUR AU - Kumar, S. AU - Lacy, M. Q. AU - Dispenzieri, A. PY - 2004 DA - 2004// TI - High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy JO - Bone Marrow Transplant VL - 34 UR - https://doi.org/10.1038/sj.bmt.1704545 DO - 10.1038/sj.bmt.1704545 ID - Kumar2004 ER - TY - JOUR AU - Dreger, P. AU - Dohner, H. AU - Ritgen, M. PY - 2010 DA - 2010// TI - Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial JO - Blood. VL - 116 UR - https://doi.org/10.1182/blood-2010-03-275420 DO - 10.1182/blood-2010-03-275420 ID - Dreger2010 ER - TY - JOUR AU - Walle, I. AU - Gansemans, Y. AU - Parren, P. W. AU - Stas, P. AU - Lasters, I. PY - 2007 DA - 2007// TI - Immunogenicity screening in protein drug development JO - Expert Opin Biol Ther VL - 7 UR - https://doi.org/10.1517/14712598.7.3.405 DO - 10.1517/14712598.7.3.405 ID - Walle2007 ER - TY - JOUR AU - Harding, F. A. AU - Stickler, M. M. AU - Razo, J. AU - DuBridge, R. B. PY - 2010 DA - 2010// TI - The immunogenicity of humanized and fully human antibodies JO - MAbs. VL - 2 UR - https://doi.org/10.4161/mabs.2.3.11641 DO - 10.4161/mabs.2.3.11641 ID - Harding2010 ER - TY - JOUR AU - Tabrizi, M. A. AU - Tseng, C. M. AU - Roskos, L. K. PY - 2006 DA - 2006// TI - Elimination mechanisms of therapeutic monoclonal antibodies JO - Drug Discov Today VL - 11 UR - https://doi.org/10.1016/S1359-6446(05)03638-X DO - 10.1016/S1359-6446(05)03638-X ID - Tabrizi2006 ER - TY - JOUR AU - Dirks, N. L. AU - Meibohm, B. PY - 2010 DA - 2010// TI - Population pharmacokinetics of therapeutic monoclonal antibodies JO - Clin Pharmacokinet VL - 49 UR - https://doi.org/10.2165/11535960-000000000-00000 DO - 10.2165/11535960-000000000-00000 ID - Dirks2010 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O'Day, S. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER -